Pulse Glucocorticoid Therapy
- 1 December 1996
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 132 (12) , 1499-1502
- https://doi.org/10.1001/archderm.1996.03890360091015
Abstract
The very high doses of drugs over a short time. Methylprednisolone (and dexamethasone in some countries) is the glucocorticoid most frequently administered this way. Doses of each pulse are not standardized but are usually 10 to 20 mg per kilogram of body weight for methylprednisolone (250-1000 mg) and 2 to 5 mg per kilogram of body weight (50-200 mg) for dexamethasone. Single doses of 500 mg of methylprednisolone and 100 mg of dexamethasone are both considered equivalent to 625 mg of prednisone.1These very high doses, sometimes termedmegadoses, are usually given as intravenous infusions over 30 minutes to 1 hour daily or every other day for a total of 1 to 5 administrations. In most indications, pulse glucocorticoid therapy is accompanied and/or followed by the continuous administration of lowor intermediate-dose glucocorticoids and/or immunosuppressive agents.Keywords
This publication has 21 references indexed in Scilit:
- Influence of treatment on the clinical course of pemphigus vulgarisJournal of the American Academy of Dermatology, 1996
- The adjuvant therapy of pemphigus. An updateArchives of Dermatology, 1996
- Mechanisms of immunosuppression by glucocorticoidsActa Endocrinologica, 1996
- Severe adverse cardiovascular effects of pulse steroid therapy: Is continuous cardiac monitoring necessary?Published by Elsevier ,1994
- CURATIVE EFFECT OF DEXAMETHASONE‐CYCLOPHOSPHAMIDE PULSE THERAPY FOR THE TREATMENT OF PEMPHIGUS VULGARISInternational Journal of Dermatology, 1992
- Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigusBritish Journal of Dermatology, 1988
- Pemphigus vulgaris. Combined treatment with intravenous corticosteroid pulse therapy, plasmapheresis, and azathioprineArchives of Dermatology, 1988
- Oral glucocorticoids and their complicationsJournal of the American Academy of Dermatology, 1986
- Systemic bioavailability and pharmacokinetics of methylprednisolone in patients with rheumatoid arthritis following ‘high‐dose’ pulse administrationBiopharmaceutics & Drug Disposition, 1983
- Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation.The Journal of Experimental Medicine, 1983